NEWAMSTERDAM PHARMA COMPANY's ticker is and the CUSIP is N62509109. A total of 35 filers reported holding NEWAMSTERDAM PHARMA COMPANY in Q4 2023. The put-call ratio across all filers is - and the average weighting 2.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $29,236,621 | -18.8% | 1,521,948 | 0.0% | 0.82% | -17.3% |
| Q1 2024 | $35,994,070 | +111.7% | 1,521,948 | 0.0% | 0.99% | +132.9% |
| Q4 2023 | $17,000,159 | +20.8% | 1,521,948 | 0.0% | 0.42% | +11.8% |
| Q3 2023 | $14,078,019 | -22.2% | 1,521,948 | 0.0% | 0.38% | -24.6% |
| Q2 2023 | $18,095,962 | -11.5% | 1,521,948 | 0.0% | 0.50% | -32.6% |
| Q1 2023 | $20,454,981 | +27.8% | 1,521,948 | 0.0% | 0.75% | +10.7% |
| Q4 2022 | $16,010,893 | – | 1,521,948 | – | 0.68% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8,300,000 | $110,058 | 13.76% |
| Medicxi Ventures Management (Jersey) Ltd | 2,000,000 | $26,520,000 | 11.36% |
| Frazier Life Sciences Management, L.P. | 9,341,551 | $125,550,445 | 9.09% |
| RA Capital Management | 4,000,000 | $53,040,000 | 1.20% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,535,723 | $33,623,687 | 0.75% |
| BVF INC/IL | 1,521,948 | $20,454,981 | 0.75% |
| GMT CAPITAL CORP | 1,083,800 | $14,371,188 | 0.56% |
| Parkman Healthcare Partners LLC | 115,000 | $1,524,900 | 0.33% |
| VIKING GLOBAL INVESTORS LP | 3,915,870 | $52,629,293 | 0.25% |
| Eversept Partners, LP | 45,856 | $608,051 | 0.04% |